Page 3 - Dr Reddy's Laboratories
Dr Reddy's Lab launches generic stomach ulcer drug in US market
DRL on Tuesday said it has launched generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules used for treatment of stomach ulcers, irritable bowel syndrome and inflammation of the colon
 "Dr Reddy's Lab launches generic stomach ulcer drug in US market")
DRL seeks a booster from Sputnik V but hurdles in scaling up remain
Even as the company investigates complaints of malpractice in the Ukraine, hurdles in scaling up the Russian vaccine remain the bigger challenge in the near term
 "DRL seeks a booster from Sputnik V but hurdles in scaling up remain")
Dr Reddy's slips over 10% post June quarter results, anonymous complaint
Gross profit margin decreased by 380 bps over the previous year and 150 bps sequentially, majorly on account of price erosion and increase in inventory provisions related to few products
Covovax denied trials on children; no nod needed for Sputnik Light
The decision comes as a setback to SII, which had sought permission to start a pediatric clinical trial of Covovax
 "Covovax denied trials on children; no nod needed for Sputnik Light")
Dr Reddy's denied approval for Phase 3 trials of Sputnik Light vaccine
After launching Sputnik V, Russia had introduced a new single-dose vaccine called Sputnik Light in May
 "Dr Reddy's denied approval for Phase 3 trials of Sputnik Light vaccine")
DRL launches DRDO drug 2-DG to treat moderate to severe Covid patients
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's
Wockhardt's growth tonic: Covid vaccines add a third prong to biz strategy
In India, Wockhardt aims to make 2 billion doses of Covid-19 vaccines within the next one or two years but has not disclosed the identity of the tie-ups
 "Wockhardt's growth tonic: Covid vaccines add a third prong to biz strategy")
Dr Reddy's recalls 2,980 bottles of cholesterol lowering drug in US
Drug major Dr Reddy's Laboratories is recalling 2,980 bottles of Atorvastatin Calcium tablets in the US due to quality issues.
 "Dr Reddy's recalls 2,980 bottles of cholesterol lowering drug in US")
BMC rejects all nine vaccine bids, in talk with Dr Reddy's for Sputnik jab
DRL has shown willingness to provide a limited quantity of the Russian shot to the civic body in June under a pilot programme
 "BMC rejects all nine vaccine bids, in talk with Dr Reddy's for Sputnik jab")
Snowman Logistics partners with Dr Reddy's for Sputnik vaccine across India
Snowman said it has entered in a strategic partnership with Dr Reddy's to provide end-to-end logistics solutions for delivery of the two-dose Sputnik Covid-19 vaccine across India
 "Snowman Logistics partners with Dr Reddy's for Sputnik vaccine across India")
2-DG drug for Covid-19 treatment: Here're the benefits and concerns
The idea behind using 2-DG in Covid-19 is that along with other anti-virals, it can help prevent replication of the Sars-CoV-2 virus in inflamed lung cells of Covid-19 patients
 "2-DG drug for Covid-19 treatment: Here're the benefits and concerns")
Covid-19: Dr Reddy's rolls out Sputnik V in India at Rs 995 per dose
The imported doses of the vaccine are priced at a maximum retail price of Rs 948 plus 5 percent GST per dose, with the possibility of a lower price point when local supply begins, says DRL
Dr Reddy's consolidated net dips 28% to Rs 554 crore in March quarter
Dr Reddy's Laboratories on Friday reported a consolidated net profit of Rs 554 crore for the quarter ended March, down 28 per cent from Rs 764 crore in the same period of the previous fiscal.The company said selling, general and administrative (SG & A) expenses went up by 17 per cent to Rs 1,430 crore due to incremental costs after the integration of Wockhardt's acquired divisions and increased freight expenses.Consolidated revenues grew 7 per cent year-on-year to Rs 4,728 crore while R & D expenses comprised 8.7 per cent of revenues at Rs 409 crore.Earnings before interest, taxes, depreciation and amortisation (EBITDA) were up 13 per cent year-on-year during Q4 FY21 at Rs 1,133 crore.For the entire year (FY21), profit after tax totalled Rs 1,915 crore on revenues of Rs 18,972 crore.Co-Chairman and MD G V Prasad said the company continued to grow across all businesses, enhanced productivity and strengthened development pipeline."We are prioritising our efforts to launch ...
 "Dr Reddy's consolidated net dips 28% to Rs 554 crore in March quarter")
Covid-19: Govt waives import duty on Remdesivir injection, raw materials
Given the shortage of supplies, the Union government last week banned the export of Remdesivir
 "Covid-19: Govt waives import duty on Remdesivir injection, raw materials")
Dr Reddy's to also use govt cold chain infra for Sputnik V distribution
The vaccine would be transported in frozen form by air and road
 "Dr Reddy's to also use govt cold chain infra for Sputnik V distribution")
Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh
Access to the private market, international sales are other factors that will impact margins
 "Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh")
India gets third Covid-19 vaccine as SEC clears Russia's Sputnik V
Final nod from DCGI soon, jab likely at $3/dose
 "India gets third Covid-19 vaccine as SEC clears Russia's Sputnik V")
Dr Reddys surges 5% as Sputnik V gets expert panel nod for emergency use
This is the third vaccine approved by India, after Covishield and Covaxin.
India drug regulator asks Dr. Reddy's for more data on Sputnik V vaccine
An expert panel of India's drug regulator sought additional data from drugmaker Dr Reddy's on its Sputnik V Covid-19 vaccine trial, in its second such request after an initial evaluation in February
Expert panel defers decision on Sputnik V Covid-19 vaccine, wants more data
Details of -25°C cold chain plan sought
 "Expert panel defers decision on Sputnik V Covid-19 vaccine, wants more data")
